The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 16, 2018

Filed:

Mar. 10, 2014
Applicant:

Kaohsiung Medical University, Kaohsiung, TW;

Inventors:

Yang-Chang Wu, Kaohsiung, TW;

Fang-Rong Chang, Kaohsiung, TW;

Tusty-Jiuan Hsieh, Kaohsiung, TW;

Suh-Hang Juo, Kaohsiung, TW;

An-Shen Lin, Taipei, TW;

Ying-Chi Du, Chiayi, TW;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 49/84 (2006.01); A61K 31/12 (2006.01); A61K 31/4439 (2006.01); C07C 49/835 (2006.01); A61K 45/06 (2006.01); A61K 31/122 (2006.01); A61K 31/352 (2006.01);
U.S. Cl.
CPC ...
A61K 31/12 (2013.01); A61K 31/122 (2013.01); A61K 31/352 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07C 49/835 (2013.01); C07C 49/84 (2013.01);
Abstract

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4'-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).


Find Patent Forward Citations

Loading…